7 results on '"Borsotti L"'
Search Results
2. Is medulloblastoma the same tumor in children and adults?
- Author
-
Giordana, Maria Teresa, Cavalla, P, Dutto, A, Borsotti, L, Chio', Adriano, and Schiffer, D.
- Subjects
Adult ,Neurons ,Adolescent ,Humans ,Cell Differentiation ,Cerebellar Neoplasms ,Child ,Neuroglia ,Cell Division ,Medulloblastoma ,Retrospective Studies - Abstract
The appearance of medulloblastoma in adult age and the uncertain overlapping of prognostic factors in pediatric and adult populations stimulate the question of whether medulloblastoma is different in adults and in children. The pathologic features, proliferation potential and glial/neuronal differentiation have been investigated in 42 adult medulloblastomas and 42 medulloblastomas of children; the quantitative data have been compared between the two groups of age. Homer-Wright rosettes, nuclear polymorphism and histologic signs of neuronal differentiation were more frequent in children cases; GFAP-positive tumor cells and desmoplastic type were more frequent in adult cases. The mean, median and rage of Lis, with PCNA and MIB-1 were significantly (p0.05) higher in adults than in children. All cases, independently from age of the patients were immunoreactive with markers of neuronal commitment (class III beta tubulin isotype, MAP-2, neurofilaments). The immunoreactivity pattern suggested a more mature neuronal character in desmoplastic cases of adults than of children and in classic cases of children than of adults. In conclusion, some phenotypic differences between childhood and adult medulloblastoma exist, but do not support a substantially different course of the disease. The higher proliferation potential in adult than in childhood cases is unexpected in a tumor of embryonal origin, and reduces the applicability of Collin's law to medulloblastoma. more...
- Published
- 1997
Catalog
3. Real-life efficacy and safety of cemiplimab in advanced cervical cancer from a nominal use program in Italy: The MITO 44 study.
- Author
-
Tuninetti V, Virano E, Salutari V, Ricotti A, Pisano C, Ducceschi M, Turitto G, Scandurra G, Petrella MC, Forestieri V, Rizzetto M, Mammoliti S, Artioli G, Cioffi R, Borsotti L, Bellero M, Rognone C, Carbone V, Ferrandina G, Mantiero M, Azzolina C, Geninatti E, Pignata S, and Valabrega G more...
- Subjects
- Humans, Female, Middle Aged, Italy, Aged, Adult, Retrospective Studies, Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Agents, Immunological adverse effects, Aged, 80 and over, Progression-Free Survival, Uterine Cervical Neoplasms drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects
- Abstract
Background: cemiplimab is an immunoglobulin G4 monoclonal antibody targeting the programmed cell death-1 receptor. A nominal use program is available in Italy in advanced cervical cancer (CC) patients treated with platinum based chemotherapy based on the results of EMPOWER-Cervical 1/GOG-3016/ENGOTcx9 trial. This real-world, retrospective cohort, multicenter study aimed at describing clinical outcomes of patients with advanced CC treated with cemiplimab in Italy., Methods: The primary objective of the study was to assess the feasibility and the replicability of the initial results in a real world setting of cemiplimab nominal use. The primary endpoint of our analysis was progression free survival (PFS). Secondary endpoints included overall response rate (ORR), overall survival (OS) and safety data., Results: From March 2022 to December 2023, 135 patients were treated in 12 Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) Centers. Forty-two percent of patients had one or more comorbidities, hypertension being the most common (23.4%). Median PFS was 4.0 months (range 3.0-6.0) and median OS was 12.0 months (12.0- NR) with no differences according to PD-L1 status. Complete response (CR) or no evidence of disease (NED) were observed in 8.6%; partial response (PR) in 21.1%, stable disease (SD) in 14.8% and progression was recorded in 44.5% of patients. Most common drug related adverse events (AEs) were anemia (39.1%) and fatigue (27.8%). Immune related AEs occurred in 18.0%., Conclusions: This study confirms the feasibility and the replicability of the cemiplimab nominal use in advanced CC, in a real-world practice in Italy., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Valentina Tuninetti: honoraria from MSD Oncology, GSK and EISAI, Elisa Virano: None declared, Vanda Salutari: Honoraria: AstraZeneca, MSD Oncology, GSK, PhamaMar, Novocure, Consulting: AstraZeneca, Novocure, Travel, Accomodations, Expenses: GSK, PharmaMar, Andrea Ricotti: None declared, Carmela Pisano: Advisory board: AstraZeneca, MSD Oncology, GSK, Monica Ducceschi: None declared, Giacinto Turitto: None declared, Giuseppa Scandurra: None declared, Maria Cristina Petrella: Honoraria from Astrazeneca, MSD, GSK, Valeria Forestieri: None declared, Monica Rizzetto: None declared, Serafina Mammoliti: None declared, Grazia Artioli: honoraria from AstraZeneca, MSD Oncology, GSK, Raffaella Cioffi: None declared, Lucia Borsotti: None declared, Marco Bellero: None declared, Chiara Rognone: None declared, Vittoria Carbone: None declared, Gabriella Ferrandina: None declared, Mara Mantiero: None declared, Carmen Azzolina: None declared, Eleonora Geninatti: None declared, Sandro Pignata: Research Funding: AstraZeneca, MSD Oncology, Roche, GSK, Pfizer, Honoraria: AstraZeneca, MSD Oncology, Roche, GSK, Novartis, EISAI, PharmaMar, Giorgio Valabrega: Consulting fees from GSK; honoraria from AstraZeneca, GSK, and MSD; travel support from AstraZeneca and PharmaMar; participation in advisory boards for AstraZeneca, EISAI, GSK, and MSD., (Copyright © 2024 Elsevier Ltd. All rights reserved.) more...
- Published
- 2024
- Full Text
- View/download PDF
4. Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience.
- Author
-
Tuninetti V, Pace L, Ghisoni E, Quarà V, Arezzo F, Palicelli A, Mandato VD, Geuna E, Cormio G, Biglia N, Borsotti L, Gallo S, Ferrero A, Jacomuzzi E, Fuso L, Pezua Sanjinez JOS, Puppo A, Caglio A, Rognone C, Turinetto M, Scotto G, Di Maio M, and Valabrega G more...
- Abstract
Background: There is poor evidence regarding sensitivity to chemotherapy in endometrial cancer (EC) based on microsatellite instability (MSI)/mismatch repair (MMR) status., Methodology: The RAME study is a retrospective analysis aiming to assess response to chemotherapy in MSI-high (h)/deficient (d) MMR and MSI-low (l)/proficient (p) MMR EC patients. Primary endpoints were recurrence-free survival (RFS) for patients with localized disease and progression-free survival (PFS) and overall survival (OS) in patients with advanced/recurrent disease., Results: A total of 312 patients treated between 2010 and 2022 in four high-volume Multicenter Italian Trial in Ovarian cancer and gynecological malignancies (MITO) centers were selected. In total, 239 patients had endometrioid EC (76.6%), 151 had FIGO stage I at diagnosis (48.9%) and 71 were MSI-h/dMMR (22.8%). Median age was 65 (range 31-91) years. Among patients with localized disease, median RFS was 100.0 months (95% CI 59.4-140.7) for MSI-l/pMMR and 120.9 months (60.0-181.8) for MSI-h/dMMR ( p = 0.39). Seventy-seven patients received first-line chemotherapy for advanced/recurrent disease. Patients with MSI-h/dMMR ECs had a significantly worse OS ( p = 0.039). In patients receiving platinum-based chemotherapy, no statistically significant differences in PFS ( p = 0.21) or OS ( p = 0.057) were detected, although PFS and OS were numerically longer in the MSI-l/pMMR population., Conclusions: Patients with metastatic MSI-h/dMMR EC receiving first-line chemotherapy had a significantly worse OS. more...
- Published
- 2023
- Full Text
- View/download PDF
5. Ki67 as a Predictor of Response to PARP Inhibitors in Platinum Sensitive BRCA Wild Type Ovarian Cancer: The MITO 37 Retrospective Study.
- Author
-
Tuninetti V, Ghisoni E, Pignata S, Picardo E, Raspagliesi F, Andreetta C, Maldi E, Artioli G, Mammoliti S, Zanchi L, Sikokis A, Biglia N, Parisi A, Mandato VD, Carella C, Cormio G, Marinaccio M, Puppo A, Paolini B, Borsotti L, Scotto G, Turinetto M, Sangiolo D, Di Maio M, and Valabrega G more...
- Abstract
Background: There is compelling need for novel biomarkers to predict response to PARP inhibitors (PARPi) in BRCA wild-type (WT) ovarian cancer (OC)., Methods: MITO 37 is a multicenter retrospective study aiming at correlating Ki67 expression at diagnosis with a clinical outcome following platinum treatment and PARPi maintenance. Clinical data were collected from high grade serous or endometroid BRCAWT OC treated with niraparib or rucaparib maintenance between 2010-2021 in 15 centers. Ki67 expression was assessed locally by certified pathologists on formalin-fixed paraffin embedded (FFPE) tissues. Median Ki67 was used as a cut-off., Results: A total of 136 patients were eligible and included in the analysis. Median Ki67 was 45.7% (range 1.0-99.9). The best response to platinum according to median Ki67 was 26.5% vs. 39.7% complete response (CR), 69.1% vs. 58.8% partial response (PR), 4.4% vs. 1.5% stable disease (SD). The best response to PARPi according to median Ki67 was 19.1% vs. 36.8% CR, 26.5% vs. 26.5% PR, 26.5 vs. 25% SD, 27.9% vs. 16.2% progressive disease (PD). No statistically significant differences in progression free survival (PFS) and overall survival (OS) were identified between low and high Ki67. PFS and OS are in line with registration trials., Conclusions: Ki67 at diagnosis did not discriminate responders to PARPi., Competing Interests: The authors declare no conflict of interest. more...
- Published
- 2023
- Full Text
- View/download PDF
6. Corpus callosum: neuropathology.
- Author
-
Schiffer D and Borsotti L
- Subjects
- Humans, Corpus Callosum pathology
- Abstract
The anatomical and histological structure of Corpus callosum is analysed, mainly in relation with cell composition and fibre distribution. The vascularization of Corpus callosum is analyzed in relation with the distribution of the supplying arteries and the fine organization of small vessels. The first part of the presentation deals with damages of corpus callosum as a consequence of hemorrhagic and ischemic vasculopathies. The lesions may be direct or indirect; the latter follow the distruction of hemispheric areas interconnecting through the corpus callosum or occur as the product of reduced flow in the territories of carotid and vertebral arteries. A special mention is dedicated to the anatomoclinical syndromes developing after damages to the anterior or posterior section of Corpus callosum. The second part deals with specific diseases such as Marchiafava-Bignami's disease, which is treated as an example of glial cell pathology and chronic edema. The third part deals with tumors. Besides lymphomas which need a separate consideration for their modality of growth, neuroepithelial tumors are discussed. The most important problem is that of invasion through the Corpus callosum. The cell traffic in this structure with all the connected questions about cell migration, adhesiveness and motility are presented. Pathology of Corpus callosum is extended also to anatomically related median structures such as fornix and septum pellucidum. The latter is one of the principal pathways of diffusion in gliomas. more...
- Published
- 1997
7. Cell proliferation and invasion in malignant gliomas.
- Author
-
Schiffer D, Cavalla P, Dutto A, and Borsotti L
- Subjects
- Cell Division, Humans, Neoplasm Invasiveness, Brain Neoplasms pathology, Glioma pathology
- Abstract
Cell proliferation and invasion were studied in sixty biopsies of malignant gliomas selected to reproduce the spreading modalities identified in ninety autopsy cases of glioblastoma. Cell proliferation was studied by the immunohistochemical demonstration of PCNA and MIB-1 and by the calculation of their labeling indexes (LI). The main finding was that cell proliferation and cell invasion are not necessarily associated. The interface between the solid tumor and the adjacent brain was represented either by a gradient of tumor cell density or by a clearcut demarcation of the tumor. In the first case the LI either did not change in the infiltration area in comparison with solid tumor or it was much lower, whereas in the second case there was a ring with a high density of labeled nuclei at the tumor periphery. Perineuronal satellites were usually positive for proliferation markers. Cells accumulated in the outer cortical layers, from a deeply located tumor, were almost negative, whereas those originating from subarachnoidal or subpial invasion showed a high LI. High LIs were also found in subarachnoidal and subpial growths, and in a cell population descending into the brain parenchyma around meningeal penetrating vessels. The relationship between cell proliferation and invasion from in vivo studies is not a direct and a simple one. more...
- Published
- 1997
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.